Lasset C, Merrouche Y, Negrier S, Rebattu P, Berille J, Bizzari J P, Chauvin F, Philip T
Medical Oncology Department, Centre Léon Bérard, Lyon, France.
Cancer Chemother Pharmacol. 1993;32(4):329-31. doi: 10.1007/BF00686182.
Sixteen patients who after prior systemic immunotherapy had progressing disease received fotemustine (100 mg/m2) i.v. on days 1, 8, and 15 followed by a 5-week rest period. In responding or stabilized patients, maintenance therapy consisted of 100 mg/m2 fotemustine given once every 3 weeks until progression on toxicity occurred. No objective response was observed. Four patients showed stable disease (median duration: 4 months; range: 3-19). The main toxicities were neutropenia (WHO grade 3 and 4: 27%) and thrombocytopenia (WHO grade 3 and 4: 27%). Fotemustine was administered on an outpatient basis and was generally well tolerated, but in our series of patients it had no antitumour activity in metastatic renal cell carcinoma after failure of immunotherapy.
16例先前接受全身免疫治疗后疾病进展的患者，在第1、8和15天静脉注射福莫司汀（100mg/m²），随后休息5周。对于病情缓解或稳定的患者，维持治疗为每3周给予100mg/m²福莫司汀，直至因毒性反应病情进展。未观察到客观缓解。4例患者病情稳定（中位持续时间：4个月；范围：3 - 19个月）。主要毒性反应为中性粒细胞减少（世界卫生组织3级和4级：27%）和血小板减少（世界卫生组织3级和4级：27%）。福莫司汀在门诊给药，总体耐受性良好，但在我们的患者系列中，免疫治疗失败后转移性肾细胞癌患者使用福莫司汀无抗肿瘤活性。
